Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerheartchemotherapyfailuremri
  Phrases that lowered it: blood pressuremmhgsystolic bloodalcohol140
• Design: factorial (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 3 (lowers risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Primary purpose: prevention (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports with a death: 11.3% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 7 (raises risk) · Sponsor's track record
• Maximum age: 70 (lowers risk) · Who can join
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 74.6% (lowers risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports before start: 40927 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 10250 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Prevention of Cardiac Dysfunction During Breast Cancer Therapy NCT03760588 · started 2019 · scored riskier than 79% of active trials completed
• Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification NCT02177175 · started 2014 · scored riskier than 56% of active trials completed
• Cardiac Safety Study in Patients With HER2 + Breast Cancer NCT01904903 · started 2013 · scored riskier than 97% of active trials completed
• STOP Heart Disease in Breast Cancer Survivors Trial NCT02674204 · started 2016 · scored riskier than 99% of active trials terminated
• Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer NCT02472353 · started 2014 · scored riskier than 57% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.